Trial · NCT03133221
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
NCT03133221, Phase 2, Completed, University of Maryland, Baltimore; results first posted 2024-09-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation. Trials, record NCT03133221. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03133221
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- NCT number
- NCT03133221
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- University of Maryland, Baltimore
- Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
- Interventions
- Zydelig
- First posted
- 2017-04-28
- Last updated
- 2025-06-27
- Results first posted
- 2024-09-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year | 1 year. | The proportion of patients who discontinued the study due to Zydelig-related adverse events. |
| Secondary | Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation. | 1- and 2-year Progression-free survival | 1- and 2-year Progression-free survival; Progression-free survival is defined as time from the date of autologous stem cell transplantation to progression, relapse and death, whichever comes first. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year | 1 year. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation. | 1- and 2-year Progression-free survival | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Discontinuation Rate Due to Zydelig-related Adverse Events at 1 Year | Oral Zydelig 150 mg BID | 5 | Participants | ||
| Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation. | Oral Zydelig 150 mg BID | Progression-free survival | 13 | Participants | |
| Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation. | Oral Zydelig 150 mg BID | 1 year post transplant relapse | 1 | Participants | |
| Progression-free Survival at 1 and 2 Years After Autologous Stem Cell Transplantation. | Oral Zydelig 150 mg BID | 2 year post transplant relapse | 3 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oral Zydelig 150 mg BID | 17 | |
| Overall Study | COMPLETED | Oral Zydelig 150 mg BID | 17 | |
| Overall Study | NOT COMPLETED | Oral Zydelig 150 mg BID | 0 |
Source ClinicalTrials.gov
Adverse events69
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain | General disorders | Oral Zydelig 150 mg BID | 2 | 17 | |
| other | Acute bilateral maxillary sinusitis | Infections and infestations | Oral Zydelig 150 mg BID | 1 | 17 | |
| other | Alkaline Phosphatase Increased | Blood and lymphatic system disorders | Oral Zydelig 150 mg BID | 1 | 17 | |
| other | ALT Decreased | Blood and lymphatic system disorders | Oral Zydelig 150 mg BID | 1 | 17 | |
| other | ALT increase | Blood and lymphatic system disorders | Oral Zydelig 150 mg BID | 4 | 17 | |
| other | Anorexia | General disorders | Oral Zydelig 150 mg BID | 1 | 17 | |
| other | Arthralgia | General disorders | Oral Zydelig 150 mg BID | 2 | 17 | |
| other | AST Decreased | Blood and lymphatic system disorders | Oral Zydelig 150 mg BID | 1 | 17 | |
| other | AST Increase | Blood and lymphatic system disorders | Oral Zydelig 150 mg BID | 5 | 17 | |
| other | Atelectasis | Respiratory, thoracic and mediastinal disorders | Oral Zydelig 150 mg BID | 1 | 17 |
1 to 10 of 69Source ClinicalTrials.gov
See all 69 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oral Zydelig 150 mg BID | 1 | 17 |
| Total, other adverse events | Oral Zydelig 150 mg BID | 9 | 17 |
| Total, serious adverse events | Oral Zydelig 150 mg BID | 1 | 17 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03133221
GET https://conductscience.org/api/trials/v1/NCT03133221/events?page=2